Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883259 | 0.77 | HCRTR2 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL14886167 | 0.76 | CCR1 (0.41) | HCRTR1HCRTR2CCR1RAB9ACCR5 | |
| SCHEMBL14885654 | 0.76 | IDH1 (0.33) | HCRTR1HCRTR2IRAK4 | |
| SCHEMBL30147690 | 0.75 | CCR1 (0.39) | HCRTR1HCRTR2CCR1RAB9ACCR5 | |
| SCHEMBL31348090 | 0.73 | IRAK4 (0.38) | HCRTR1HCRTR2CCR1RAB9ACCR5 | |
| SCHEMBL19480728 | 0.73 | CCR1 (0.38) | HCRTR1HCRTR2CCR1RAB9ACCR5 | |
| SCHEMBL25510487 | 0.73 | CYP1A2 (0.42) | KDM4EHPGDHSD17B10 | |
| SCHEMBL25510486 | 0.71 | SMN1; SMN2 (0.41) | KDM4EHPGDHSD17B10 | |
| SCHEMBL20365554 | 0.69 | ALDH1A1 (0.46) | KDM4EHPGDHSD17B10 | |
| SCHEMBL25510491 | 0.69 | TSHR (0.49) | KDM4EUSP2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR1 2/4885HCRTR2 1/4885CCR1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.